Skip to main content
. 2017 Oct 23;66(2):229–236. doi: 10.1093/cid/cix779

Table 2.

Treatment Outcomes; Parasite and Fever Clearance

Variable AL Arm (n = 58) CQ Arm (n = 65) P Value
Adequate parasitological and clinical response, No./total (%)a
 Day 28 48/48 (100) 57/57 (100)
 Day 42 46/46 (100) 53/53 (100)
Parasitological response: any parasitemia
 24 h
  Negative results, No. (%; 95% CI) 44 (76; 63–86) 39 (60; 47–72) .06
  Difference in risk (95% CI), % 16 (0–32)
  Risk ratio (95% CI) 1.3 (1.0–1.6)
 48 h
  Negative results, No. (%; 95% CI) 58 (100; 93.8–100) 65 (100; 94.5–100)
 PCT, median (IQR) [range], h 18 (18–24) [6–42] 24 (18–30) [12–48] .02b
Parasitological response: parasitemia >1000/μLa n = 35 (60%) n = 38 (58%)
 24 h
  Negative results, No. (%; 95% CI) 22 (63; 46–80) 15 (40; 23–56) .047b
  Difference in risk (95% CI), % 23 (0–46)
  Risk ratio (95% CI) 1.6 (1.0–2.5)
 48 h
  Negative results, No. (%; 95% CI) 35 (100; 90.0–100) 38 (100; 90.7–100)
 PCT, median (IQR) [range], h 24 (18–30) [12–42] 30 (24–36) [12–48] .02b
 Slope of curve for log10-normalized parasite clearance mean (95% CI), kc 0.27 (.25–.29) 0.22 (.20–.24) .002b
 Lag phase present, No. (%) 14 (40.0) 13 (34.2) .61
 Lag phase duration, mean (95% CI), h 2.9 (1.6–4.3) 2.5 (1.3–3.7) .81
 PCT, mean (95% CI), h
 50% PCT d 7.2 (5.6–8.9) 8.2 (6.4–10.1) .51
 90% PCT 13.7 (11.8–15.7) 15.6 (13.6–17.7) .14
 99% PCT 23.1 (20.3–25.8) 26.9 (24.2–29.6) .03b
Fever clearance time, median (IQR) [range], h 18 (12–24) [6–60] 12 (12–30) [6–48] .87

Abbreviations: AL, artemether-lumefantrine; CI, confidence interval; CQ, chloroquine; IQR, interquartile range; PCT, parasite clearance time.

aAdequate parasitological and clinical response is defined elsewhere [21].

bSignificant difference (P < .05).

cIncluding only those with parasite counts >1000/μL according to the WorldWide Antimalarial Resistance Network (WWARN) parasite clearance method [29].

dReduction in parasite count by 50%.